Impact of total body fat on bioavailability and biofunctionality of isoflavones in postmenopausal women

Impact of total body fat on bioavailability and biofunctionality of isoflavones in postmenopausal women - Body fat and isoflavone biofunctionality

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00000708

Enrollment

400

Registered

2011-02-10

Start date

2012-01-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E66.09

Interventions

Group 1: isoflavone extract from soy (Novasoy®), 1 capsule á 100mg orally per day for 12 weeks Group 2: placebo

Eligibility

Sex/Gender

Female

Age

No minimum to 74 Years

Inclusion criteria

Inclusion criteria: postmenopausal women aged below 75y, BMI 20-25 and above 30 kg/m2, non-smoker who gave written consent

Exclusion criteria

Exclusion criteria: hormone replacement therapy, breast cancer, serious diseases related to resorption, digestion, metabolism or excretion, use of supplements or medication withon the last 3 months that could have an impact on major parameter, non-compliant volunteers

Design outcomes

Secondary

Measure	Time frame
isoflavones and metabolites in lipoproteins (ultracentrifugation, LC-MS/MS), adipokines (ELISA) und sex hormones (HPLC) in serum, protein expression (flow cytometry, western blotting) und methylation pattern in peripheral lymphocytes (MASS-Array); before and after 12 weeks of intervention.	—

Primary

Measure	Time frame
isoflavones plasma concentrations, before and 4, 8, and 12 weeks after Intervention, LC-MS/MS analysis	—

Countries

Germany

Contacts

Public ContactAnita Kriebel

Max Rubner-Institut

anita.kriebel@mri.bund.de0721 6625413

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026